Results 231 to 240 of about 9,499,844 (341)

Pharmacodynamic Effects of Litifilimab in Lupus in a Randomized, Placebo‐Controlled Phase 2 Study: Rapid and Sustained Reductions in Type I Interferon‐Associated Gene Expression and Cytokines

open access: yesArthritis &Rheumatology, EarlyView.
Objective The pharmacodynamic effects of litifilimab on type I interferon (IFN) response and correlations with clinical outcomes were investigated in systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Methods Participants from part A (SLE) or part B (CLE with or without SLE) of the randomized phase 2 LILAC trial who received ...
Richard Furie   +8 more
wiley   +1 more source

Whole-body vibration and musculoskeletal diseases in professional truck drivers [PDF]

open access: gold, 2016
Geraldo Fabiano de Souza Moraes   +3 more
openalex   +1 more source

A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To compare the efficacy of abatacept to placebo for the treatment of relapsing, nonsevere granulomatosis with polyangiitis (GPA). Methods In this multicenter trial, eligible patients with relapsing, nonsevere GPA were randomized to receive abatacept 125 mg subcutaneously once a week or placebo, both together with prednisone 30 mg/day (or ...
Carol A. Langford   +155 more
wiley   +1 more source

The impact of uric acid on musculoskeletal diseases: clinical associations and underlying mechanisms. [PDF]

open access: yesFront Endocrinol (Lausanne)
Zhang J   +6 more
europepmc   +1 more source

Rehabilitation Interventions Delivered via Telehealth to Support Self‐Management of Rheumatic and Musculoskeletal Disease: A Scoping Review

open access: yesArthritis &Rheumatology, EarlyView.
Objective To identify and summarize existing telerehabilitation interventions for people living with rheumatic and musculoskeletal diseases (RMDs), including the rehabilitation components, the technology used, the type of health care professional (HCP) interaction, and how the effectiveness is evaluated.
Thomas A. Ingram   +5 more
wiley   +1 more source

American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel

open access: yesArthritis &Rheumatology, EarlyView.
Objective Vacuoles E1 enzyme X‐linked autoinflammatory somatic syndrome (VEXAS) is a recently identified rare genetic disorder associated with somatic mutations in the UBA1 gene. VEXAS presents with a combination of inflammatory and hematologic manifestations, leading to increased morbidity and mortality.
Arsene Mekinian   +111 more
wiley   +1 more source

Home - About - Disclaimer - Privacy